Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | IDE | P14735 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KDM6B | O15054 | 1/20 | 0.51 |
| ▸ | KDM6A | O15550 | 1/20 | 0.51 |
| ▸ | TET3 | O43151 | 1/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.51 |
| ▸ | KDM4B | O94953 | 1/20 | 0.51 |
| ▸ | KDM5C | P41229 | 1/20 | 0.51 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.51 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.51 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.51 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10566172 | 0.84 | ERN1 (0.54) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL23640339 | 0.84 | ERN1 (0.54) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL69562 | 0.82 | KDM4E (0.52) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL29415433 | 0.82 | KDM4E (0.52) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL1134041 | 0.81 | P2RX7 (0.53) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL14888067 | 0.81 | KDM4E (0.50) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL3986493 | 0.81 | MEN1 (0.58) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL8657628 | 0.80 | KDM4E (0.56) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL23640340 | 0.80 | ERN1 (0.47) | ERN1MEN1KMT2ARAB9ABLM | |
| SCHEMBL730049 | 0.77 | CA12 (0.51) | ERN1MEN1KMT2ARAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| CN-104284655-A | Methods of treating lactose intolerance | NOGRA PHARMA LTD | 2015-01-14 | — | — | CN | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | claimed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | claimed |
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | claimed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | claimed |
| CN-101243043-A | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INT LTD (IE) | 2008-08-13 | — | — | CN | claimed |
| EP-1910275-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010514-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | claimed |
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | disclosed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| CN-116602950-A | Methods of treating fibrosis | 诺格拉制药有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-0102833-B1 | CARBOXYLATION OF METAL ARYLOXIDES | Euroceltique S.A. (LU) | 1986-08-13 | — | — | EP | disclosed |
| US-4604388-A | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof in a method of counteracting histamine | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-08-05 | — | — | US | disclosed |
| US-4592866-A | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0102833-A1 | Carboxylation of metal aryloxides | Euroceltique S.A. (LU) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118357-A1 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | ERN1 2723/4885MEN1 3937/4885KMT2A 4440/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | ERN1 3836/4885MEN1 4490/4885KMT2A 3951/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | ERN1 3836/4885MEN1 4490/4885KMT2A 3951/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | ERN1 3438/4885MEN1 4879/4885KMT2A 3204/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | ERN1 3836/4885MEN1 4490/4885KMT2A 3951/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | ERN1 3438/4885MEN1 4879/4885KMT2A 3204/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | ERN1 2791/4885MEN1 4786/4885KMT2A 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.